Top Markets
Coin of the day
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rang in Aktien #40869
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Aktienkurs
$0.02765
Zuletzt synchronisiert: 2024-12-23
Marktkapitalisierung
$69.04K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Histogen Inc. (HSTO)

Kategorie

Kursverlauf für Histogen Inc. (HSTO)
Höchster Schlusskurs: $0.02 am 2024-12-01

Niedrigster Schlusskurs: $186.88 am 2013-07-01
Kursverlauf der Aktie von Histogen Inc. von 2013 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 -28.82%
2023 -66.41%
2022 -88.05%
2021 -66.17%
2020 -68.37%
2019 -78.98%
2018 -59.92%
2017 45.54%
2016 4.61%
2015 -61.12%
2014 15.35%
2013 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$517.18 30.63%
US
$857.76 32.66%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE